research use only
Cat.No.S3699
| Related Targets | Akt Wnt/beta-catenin PKC HSP ROCK Microtubule Associated Integrin Bcr-Abl Actin FAK |
|---|---|
| Other MLCK Inhibitors | ML-7 HCl Sevasemten |
|
In vitro |
DMSO
: 20 mg/mL
(197.82 mM)
Water : 20 mg/mL Ethanol : 20 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 101.10 | Formula | C4H7NO2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 57-71-6 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Diacetyl monoxime, Diacetylmonoxime | Smiles | CC(=NO)C(=O)C | ||
| Targets/IC50/Ki |
skeletal muscle myosin-II
|
|---|---|
| In vitro |
BDM inhibits skeletal muscle myosin-II, but it does not inhibit the ATPase activity of the other myosins. BDM has a broad effect on many non-myosin proteins (many uncharacterized), and thus should not be used in whole-cell experiments as a myosin inhibitor. BDM inhibits the L-type Ca2+-channel and reduces the opening probability, thereby increasing the closed time of this particular channel. BDM drives nonspecific protein dephosphorylation of many cellular proteins, including ion channels.
|
| In vivo |
BDM significant lowers the blood pressure in normo- and hypertensive rats. BDM has been shown to improve right atrial function in a porcine model of allogenic heart transplantation.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05391776 | Unknown status | Osteoporosis |
HJB (Hangzhou) Co. Ltd. |
April 28 2022 | Phase 1 |
| NCT01721187 | Completed | Fasting|Fed |
Duke-NUS Graduate Medical School|Singapore Institute for Clinical Sciences |
October 2012 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.